Table 1.
Baseline characteristics of patients in BLISS-52 and BLISS-76
| BLISS-52 and BLISS-76 (n = 1684) | |
|---|---|
| Female sex | 1585 (94%) |
| Ethnicity | |
| Asian | 353 (21%) |
| Black/African-American | 146 (9%) |
| Indigenous Americana | 374 (22%) |
| White/Caucasian | 798 (47%) |
| Country/Continent | |
| Asia Pacific | 339 (20.1%) |
| Canada/USA | 436 (25.9%) |
| Europe/Israel | 393 (23.3%) |
| Latin America | 516 (30.6%) |
| Age (years) | 37.8 (11.5) |
| Mean BMI (week 0–52) | 25.8 (5.9) |
| SDI score | 0.8 (1.2); (N = 1683) |
| SLE disease duration (years) | 6.4 (6.3) |
| SLEDAI-2K score | 10.0 (3.8) |
| Clinical SLEDAI-2K score | 7.4 (3.6) |
| SELENA-SLEDAI physician’s global assessment score | 1.4 (0.5) |
| Prednisone equivalent dose (mg/day) | 10.8 (8.7) |
Data are presented as n (%) or mean (s.d.).
a
Alaska Native or American Indian from North, South or Central America.
SDI: Systemic Lupus International Collaborating Clinics (SLICC)/ACR Damage Index; SLEDAI-2K: SLEDAI 2000; SELENA-SLEDAI: Safety of Estrogens in Lupus Erythematosus National Assessment version of the SLEDAI.